Skip to content

MDGL MADRIGAL PHARMACEUTICALS INC

Follow

Stock (common), issuer CIK 1157601

Filings received so far for Q3 2026: 8 13F filers report a position in MDGL shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.

13D and 13G filers

No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.

Insider trades

No Form 4 transaction on this security in the data.

13F holders, Q3 2026

Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.

HolderSharesValue% of portfolioChangeSource
Farther Finance Advisors, LLC862$434K<0.01%+75613F-HRTimeline
CoreCap Advisors, LLC280$141K<0.01%013F-HRTimeline
GAMMA Investing LLC279$141K<0.01%+10713F-HRTimeline
EASTERN BANK65$32.8K<0.01%013F-HRTimeline
MassMutual Private Wealth & Trust, FSB10$5.04K<0.01%-113F-HRTimeline
TOTH FINANCIAL ADVISORY CORP3$1.51K<0.01%-1,99713F-HRTimeline
Versant Capital Management, Inc3$1.51K<0.01%new13F-HRTimeline
CX Institutional2$1K<0.01%013F-HRTimeline